CHRS Coherus Oncology, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CHRS matters now
Coherus Oncology, Inc. (CHRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.54 with -5.52% on the session and $188.5M in market capitalization; recent performance reads 1-month +0.00% and YTD +4.23%.
The latest financial table shown here is Q1 2026, with revenue of $12.3M, net income of $-37.9M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E 1.17 and FCF yield -94.2%.
The latest indexable market news headline is "Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Newton Charles W. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
1.17
PEG
0.00
P/B
2.57
P/S
3.86
EV/EBITDA
-0.75
DCF Value
$-0.26
FCF Yield
-94.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.0%
Operating Margin
-362.1%
Net Margin
-323.5%
ROE
-174.7%
ROA
-57.0%
ROIC
-125.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.3M | $-37.9M | $-0.28 |
| Q4 2025 | $12.7M | $-37.3M | $-0.31 |
| FY 2025 | $42.2M | $-170.3M | $-1.45 |
| Q3 2025 | $11.6M | $-35.1M | $-0.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.02
Target (Median)
$6.00
Target Range
$1.05 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.96
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.